Tociluzumab

Phase 3Monoclonal antibody

Tociluzumab is one of 67 small molecule programs targeting Relapsed or Refractory Follicular Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed or Refractory Follicular LymphomaActive, not recruiting

Follicular LymphomaActive, not recruiting

Chronic Granulomatous DiseaseActive, not recruiting

Relapsed or Refractory Follicular LymphomaPhase 3

Active, not recruiting

Follicular LymphomaPhase 3

Active, not recruiting

Chronic Granulomatous DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

201 competitors in Follicular Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

83 2

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

26 3

Fludara

Sanofi

Phase 3

8 4

Zydelig

Gilead

Phase 3

6 5

Rayos

RRoxane Laboratories

Phase 3

14 6

Kesimpta

Novartis

Phase 3

2 7

Imbruvica

PPharmacyclics LLC.

Phase 3

10 8

Tazverik

EEpizyme, Inc.

Phase 3

7 9

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

5 10

Copiktra

SSecuraBio

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Active, not recruiting

Relapsed or Refractory Follicular Lymphoma

NCT04712097

Q4 2032

Phase 1/2Recruiting

Chronic Granulomatous Disease

NCT05463133

Clinical

Trials by Indication[1]

Chronic Granulomatous Disease1 trial

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05463133·50 enrolled

Relapsed or Refractory Follicular Lymphoma1 trial

Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Non-Randomized Single Arm US Extension of Mosunetuzumab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04712097·478 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tociluzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tociluzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tociluzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Roche

Tociluzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Q4 2032

Trials by Indication[1]

Chronic Granulomatous Disease1 trial

Relapsed or Refractory Follicular Lymphoma1 trial

References

Drug Info

Quick Facts

Related News